



Appendix 5: flow charts


Single site brain and CNS cancer studies



Multiple site brain and CNS cancer studies




Single site breast cancer studies



Key: B&A = before and after study

Multiple site breast cancer studies



Key: B&A = before and after study

Audit number	N Breast
(WTA 223)	104
(WTA 212)	363
(WTA 220)	510
(WTA 213)	646
(WTA 214)	983
(WTA 215)	1024
(WTA 222)	3288


Audit number	N Breast
(WTA 208)	23
(WTA 227)	23
(WTA 224)	49
(WTA 221) (B&A)	

Audit number	N Breast
(WTA 218)	261


Audit number	N Breast
(WTA 225)	146
(WTA 218) (B&A)	2504

Audit number	N Breast
(WTA 226)	50
(WTA 209)	63
(WTA 210)	87
(WTA 217)	110
(WTA 219)	170
(WTA 232)	170
(WTA 206)	214
(WTA 231)	217
(WTA 229)	243
(WTA 230)	269
(WTA 233)	449
(WTA 234)	494
(WTA 207)	706

Single site children's cancer studies




Multiple site children's cancer studies




Audit number	N Children's cancers
(WTA 224)	3

Audit number	N Children's cancers
(WTA 207)	1
(WTA 230)	1
(WTA 206)	1
(WTA 233)	2
(WTA 232)	2
(WTA 231)	5
(WTA 234)	11


Single site lower GI cancer studies




Multiple site lower GI cancer studies



Single site upper GI cancer studies



Multiple site upper GI cancer studies



Multiple site studies including GI upper (n=31)

Research Study (n=0)

Clinical audit (n=31)

Below threshold (n=4)

Above threshold (n=27)

Audit number
(WTA 239)
(WTA 211)
(WTA 216)
(WTA 237)

Population = cancer patients and referrals (n=8)

Population = cancer patients (n=3)

Population = referrals (n=16)

Audit number	N Upper GI
(WTA 223)	48
(WTA 235)	64
(WTA 212)	64
(WTA 220)	295
(WTA 213)	636
(WTA 215)	813
(WTA 214)	834
(WTA 222)	995

Audit number	N Upper GI
(WTA 208)	7
(WTA 238)	10
(WTA 227)	13


All referrals (n=2)

Urgent referrals (n=14)


Audit number	N Upper GI
(WTA 225)	45
(WTA 218) (B&A)	

Audit number	N Upper GI
(WTA 217)	13
(WTA 219)	20
(WTA 209)	32
(WTA 226)	46
(WTA 210)	48
(WTA 231)	52
(WTA 232)	70
(WTA 206)	77
(WTA 230)	143
(WTA 229)	154
(WTA 233)	204
(WTA 234)	252
(WTA 207)	449
(WTA 236) (B&A)	70

Single site gynaecological cancer studies



Multiple site gynaecological cancer studies



Multiple site studies including Gynaecological (n=29)

Research Study (n=0)

Clinical audit (n=29)

Below threshold (n=3)

Audit number
(WTA 211)
(WTA 216)
(WTA 239)

Above threshold (n=26)

Population = cancer patients and referrals (n=7)

Population = cancer patients (n=4)

Population = referrals (n=15)

Audit number	N Gynaecological
(WTA 212)	51
(WTA 223)	57
(WTA 220)	220
(WTA 213)	621
(WTA 222)	821
(WTA 215)	1013
(WTA 214)	1193

Audit number	N Gynaecological
(WTA 208)	8
(WTA 227)	16
(WTA 238)	19
(WTA 221) (B&A)	

Unclear (n=1)

Audit number	N Gynaecological
(WTA 228)	33


All referrals (n=1)

Audit number	N Gynaecological
(WTA 225)	11


Urgent referrals (n=13)

Audit number	N Gynaecological
(WTA 217)	27
(WTA 209)	29
(WTA 226)	29
(WTA 210)	36
(WTA 231)	49
(WTA 232)	65
(WTA 206)	73
(WTA 240)	74
(WTA 230)	118
(WTA 229)	128
(WTA 233)	176
(WTA 234)	238
(WTA 207)	242

Single site haematological cancer studies



Multiple site haematological cancer studies




Audit number	N Haematological
(WTA 212)	11
(WTA 215)	175
(WTA 213)	212
(WTA 214)	239

Audit number	N Haematological
(WTA 208)	1
(WTA 227)	1
(WTA 224)	1
(WTA 221) (B&A)	


Audit number	N Haematological
(WTA 225)	3
(WTA 219) (B&A)	753

Audit number	N Haematological
(WTA 226)	3
(WTA 209)	4
(WTA 206)	5
(WTA 231)	5
(WTA 229)	8
(WTA 232)	8
(WTA 230)	10
(WTA 207)	14
(WTA 234)	20
(WTA 233)	23


Single site head and neck cancer studies



Multiple site head and neck cancer studies



Single site lung cancer studies




Audit number
(WTA 143)
(WTA 139)
(WTA 141)
(WTA 144)
(WTA 146)

Audit number	Sample size
(WTA 138)	10
(WTA 137)	10

Audit number	Sample size
(WTA 145)	80
(WTA 148)	129
(WTA 149)	288
(WTA 151)	640

Audit number	Sample size
(WTA 140)	27
(WTA 147)	115
(WTA 150)	414
(WTA 142) (B&A)	45

Multiple site lung cancer studies



Audit number
(WTA 239)
(WTA 211)
(WTA 216)

Population = cancer patients and referrals (n=6)

Audit number	N Lung cancer
(WTA 212)	13
(WTA 223)	15
(WTA 214)	474
(WTA 213)	494
(WTA 215)	571
(WTA 222)	810

Population = cancer patients (n=3)

Audit number	N Lung cancer
(WTA 227)	4
(WTA 208)	23
(WTA 221) (B&A)	

Population = referrals (n=16)

Unclear (n=1)

Audit number	N Lung cancer
(WTA 228)	30


All referrals (n=2)

Audit number	N Lung cancer
(WTA 225)	16
(WTA 218) (B&A)	1684

Urgent referrals (n=13)

Audit number	N Lung cancer
(WTA 209)	12
(WTA 217)	18
(WTA 226)	19
(WTA 210)	25
(WTA 231)	37
(WTA 206)	46
(WTA 232)	56
(WTA 240)	79
(WTA 230)	85
(WTA 234)	103
(WTA 233)	103
(WTA 207)	142
(WTA 229)	231

Multiple site sarcoma studies




Audit number
(WTA 216)

Audit number	N Sarcomas
(WTA 208)	1

Audit number	N Sarcomas
(WTA 210)	1
(WTA 231)	3
(WTA 232)	4
(WTA 209)	5
(WTA 206)	5
(WTA 230)	6
(WTA 234)	8
(WTA 207)	10
(WTA 233)	11

Single site skin cancer studies



Audit number	Sample size
(WTA 152) (B&A)	9
(WTA 168) (B&A)	100

Audit number	(WTA 160)	(WTA 189)
(WTA 178)	(WTA 162)	(WTA 153)
(WTA 183)	(WTA 171)	(WTA 155)
(WTA 154)	(WTA 176)	(WTA 165)
(WTA 158)	(WTA 186)	


Audit number	Sample size
(WTA 163)	64
(WTA 164)	76
(WTA 169)	103
(WTA 175)	160
(WTA 185)	384

Audit number	Sample size
(WTA 161)	57
(WTA 166)	86

Audit number	Sample size
(WTA 177)	183
(WTA 184)	368
(WTA 187)	476

Audit number	Sample size
(WTA 156)	32
(WTA 157)	41
(WTA 159)	45
(WTA 167)	88
(WTA 170)	112
(WTA 172)	155
(WTA 174)	157
(WTA 173)	157
(WTA 179)	211
(WTA 180)	276
(WTA 181)	291
(WTA 182)	316
(WTA 188)	580

Multiple site skin cancer studies




Audit number
(WTA 239)
(WTA 211)
(WTA 216)

Audit number	N Skin
(WTA 223)	4
(WTA 212)	217
(WTA 214)	1328
(WTA 313)	1448
(WTA 222)	1580
(WTA 215)	1677

Audit number	N Skin
(WTA 228)	64

Audit number	N Skin
(WTA 209)	28
(WTA 210)	28
(WTA 231)	46
(WTA 217)	75
(WTA 232)	79
(WTA 206)	116
(WTA 230)	126
(WTA 233)	239
(WTA 207)	265
(WTA 229)	309
(WTA 234)	312

Single site urological cancer studies



Population = all referrals (n=1)

Audit number	Sample size
(WTA 198)	64

Audit number
(WTA 190)
(WTA 191)
(WTA 192)
(WTA 205)

Population = cancer patients (n=4)

Audit number	Sample size
(WTA 203)	11
(WTA 204)	13
(WTA 195)	34
(WTA 202)	123

Population = referrals (n=6)

All referrals (n=2)

Audit number	Sample size
(WTA 197)	50
(WTA 200)	82


Urgent referrals (n=4)

Audit number	Sample size
(WTA 193)	30
(WTA 194)	32
(WTA 196)	40
(WTA 201)	150

Population = cancer patients and referrals (n=1)

Audit number	Sample size
(WTA 199)	73

Multiple site urological cancer studies



Multiple site studies including Urological (n=27)

Research Study (n=0)

Clinical audit (n=27)

Below threshold (n=3)

Audit number
(WTA 211)
(WTA 216)
(WTA 239)

Above threshold (n=24)

Population = cancer patients and referrals (n=6)

Population = cancer patients (n=4)

Population = referrals (n=14)

Audit number	N Urological
(WTA 223)	54
(WTA 212)	95
(WTA 214)	442
(WTA 215)	475
(WTA 213)	654
(WTA 222)	1190

Audit number	N Urological
(WTA 208)	2
(WTA 224)	3
(WTA 227)	14
(WTA 221) (B&A)	

Unclear (n=1)

Audit number	N Urological
(WTA 22*)	48

All referrals (n=1)

Audit number	N Urological
(WTA 225)	29

Urgent referrals (n=12)

Audit number	N Urological
(WTA 209)	27
(WTA 226)	28
(WTA 231)	41
(WTA 210)	41
(WTA 217)	43
(WTA 232)	79
(WTA 206)	83
(WTA 230)	90
(WTA 229)	241
(WTA 207)	263
(WTA 233)	275
(WTA 234)	333

Site not stated cancers studies

